NEW YORK (GenomeWeb) – WaferGen Biosystems announced today that it has completed an offering of common stock and warrants that brought in gross proceeds of $20 million.

The offering comprises 2,000 units priced at $10,000 per unit. Each unit consists of 2,000 shares of common stock and 2,000 warrants to purchase shares of the firm's common stock. In total, 4 million shares of common stock and warrants to purchase 4 million shares were issued in the offering. The warrants have a term of five years and an exercise price of $5 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.